Wonder
Log in
Research Outline
Prepared for Kalen B. | Delivered January 16, 2020
Novo Nordisk Pipeline
Review your project details
Goals
To understand Novo Nordisk's drug / treatment pipeline and the drug advancements they are making.
View less
Early Findings
N
o
v
o
N
o
r
d
i
s
k
currently has
17 drugs/treatments
in the pipeline.
Phase I
L
A
I
S
e
m
a
is a type 1 diabetes treatment, once-weekly combination of once-weekly insulin LAI287 and once-weekly injectable GLP-1
s
e
m
a
g
l
u
t
i
d
e
.
FSI965
is a basal insulin treatment for type 1 and 2 diabetes.
PYY 1562
is intended to treat diabetes using peptide YY, an appetite-regulating hormone in combination with
s
e
m
a
g
l
u
t
i
d
e
.
GG-co-agonist 1177
is a glucagon-GLP-1 co-agonist for the treatment of obesity.
T
r
i
-
a
g
o
n
i
s
t
1706
is intended to treat obesity. The treatment is a triple full agonist, containing native human glucagon-like peptide 1 (GLP-1), gastric inhibitory peptide (GIP) and glucagon receptors (GCG).
PYY 1875
is an obesity treatment using
s
e
m
a
g
l
u
t
i
d
e
and an appetite regulating hormone.
LA-GDF15
is a human GDF15, a stress-induced
c
y
t
o
k
i
n
e
. The drug suppresses appetite for the treatment of obesity.
Eclipse
is EPI01 an oral combination for the treatment of sickle cell disease.
PCSK9i
is intended to treat
h
y
p
e
r
c
h
o
l
e
s
t
e
r
o
l
a
e
m
i
a
.
Phase II
Anti-IL 21 GLP-1 T1D
is a beta-cell preservation treatment for the treatment of type 1 diabetes.
LAI287
is a long-acting basal insulin analogue for the treatment of types 1 and 2 diabetes.
AM833
is a long-acting
a
m
y
l
i
n
analogue intended to treat obesity.
S
e
m
a
g
l
u
t
i
d
e
NASH
is a long-acting GLP-1 analogue to treat non-alcoholic fatty liver disease (NASH).
Phase III
Semaglutide Obesity
C
o
n
c
i
z
u
m
a
b
S
o
m
a
p
a
c
i
t
a
n
Filed
Oral
s
e
m
a
g
l
u
t
i
d
e
Early Findings
Information on phase I and II are not very detailed and information is only available through
N
o
v
o
N
o
r
d
i
s
k
.
Information on Phase III and filed treatments and drugs is more readily available through press releases and abstracts.
View less